Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 All components of 3-point MACE contributed to the reduction in cardiovascular risk in the LEADER trial Cardiovascular death Patients with an Non-fatal myocardial infarction Slide 63 Non-fatal stroke VictozaⓇ Placebo event (%) 10 10 HR = 0.78 8 95% CI (0.66;0.94) p=0.007 80 6 4 2 0 6 4 HR = 0.88 95% CI (0.75;1.03) p=0.11 10 HR = 0.89 95% CI (0.72;1.11) 8- p=0.30 160 4 2 2 0 0 18 36 54 18 36 54 18 36 54 Months Months Months HR: hazard ratio; CI: confidence interval Source: Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England journal of medicine. 2016; In Press changing diabetes® novo nordisk

View entire presentation